Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma

Hepatology

Volumn 56, Issue 2, 2012, Pages 789-790

  Bettinger, Dominik ^a   Schultheiß, Michael ^a   Knüppel, Eva ^a   Thimme, Robert ^a   Blum, Hubert E ^a   Spangenberg, Hans Christian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ANOREXIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; FATIGUE; HAND FOOT SYNDROME; HUMAN; LETTER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES;

EID: 84864360500     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25637     Document Type: Letter

References (4)

1. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-2063.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
3. Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol 2011; 23: 1233-1238.
4. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.